Navigation Links
Low Levels of Brain Chemical May Control Appetite
Date:8/27/2008

Finding could lead to new drugs in fight against obesity, study says

WEDNESDAY, Aug. 27 (HealthDay News) -- A chemical produced in the brain may play a role in regulating appetite and the likelihood of becoming obese, according to a new study.

For the study, researchers looked at a group of 33 people who had WAGR syndrome, a genetic condition that occurs in one in 500,000 to a million people. WAGR is an acronym for the symptoms that accompany the condition: Wilms' tumor (tumor of the kidneys), aniridia (absence of the iris), genital and urinary tract abnormalties, and mental retardation.

Some people with WAGR syndrome lack a gene for the brain chemical, brain-derived neurotrophic factor (BDNF). Animal studies have suggested that BDNF may help control appetite and weight.

The researchers found that 19 (58 percent) of the 33 study participants had deletions of all or a major proportion of one copy of the gene for BDNF and had correspondingly low blood levels of BDNF.

These 19 participants were all obese by age 10 and had a strong tendency to overeat. The participants who had two working copies of the BDNF gene, on the other hand, were no more likely to develop obesity in childhood than the general population and did not report unusually high levels of overeating.

"This is a promising new lead in the search for biological pathways that contribute to obesity," Dr. Duane Alexander, director of the U.S. National Institute of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), said in an institute press release. "This finding may eventually lead to the development of new drugs to regulate appetite in people who have not had success with other treatments."

The findings are published in the Aug. 28 issue of the New England Journal of Medicine.

According to senior study author Dr. Jack A. Yanovski, of the NICHD's Unit on Growth and Obesity, BDNF is thought to work in combination with a variety of other substances that regulate appetite and body weight, including the appetite-signaling hormone leptin.

Future research looking into the relationship between BDNF and leptin may lead to the development of new therapies for obesity.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about obesity.



-- Krisha McCoy



SOURCE: U.S. National Institute of Child Health and Human Development, news release, Aug. 27, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. The Highlands at Wyomissing Invests in Voice-Assisted Care to Take Excellence in Retirement Living to New Levels
2. Earthjustice/EIP Report: Dangerous Mercury Pollution From Unregulated Cement Kilns in U.S. About Twice as High as Levels Previously Projected by EPA
3. CSHL scientists correlate enzyme expression levels with chemotherapy drug response
4. Low Iron Levels Cut Cancer Risk in Men With PAD
5. FTC Acts to Prevent Tobacco Industry Deception About Tar, Nicotine Levels; Congress Should Go Further by Giving FDA Authority Over Tobacco Products
6. Moms Vitamin D Levels Affect Babys Dental Health
7. American Lung Association Urges People Living Near Wildfires to Protect Themselves Against Staggering Levels of Unhealthy Air Pollution
8. Research Links Low HDL Levels With Memory Loss
9. UK and US guidelines on kids physical activity levels need rethinking
10. Overcrowding and understaffing in hospitals increases levels of MRSA infections
11. Local Blood Supply at Low Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader ... been awarded a contract by the Center for Medicare and Medicaid Services (CMS). ... the enterprise use of Agile methodologies in a consistent and high value manner ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
Breaking Medicine Technology: